This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays

Tipranks - Tipranks - Thu May 28, 5:00AM CDT

Barclays analyst Etzer Darout reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $253.00.

Memorial Day Sale – Claim 70% Off TipRanks

Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Oruka Therapeutics. According to TipRanks, Darout has an average return of 25.9% and a 56.03% success rate on recommended stocks.

In a report released on May 22, Piper Sandler also assigned a Buy rating to the stock with a $301.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.07 billion and a net profit of $293.1 million. In comparison, last year the company earned a revenue of $897.84 million and had a GAAP net loss of $92.54 million

Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Most recently, in March 2026, Patricia Carr, the SVP & CAO of JAZZ sold 2,723.00 shares for a total of $503,645.50.

Read More on JAZZ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).